Previous 10 | Next 10 |
ARLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options and restricted stock units (RSUs) to new employees as inducement awards outside the Company’s Amended and Restated 2017 Equity ...
ARLINGTON, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it will prese...
2023-05-24 13:33:04 ET In its preliminary annual 2023 Russell indexes reconstitution, a total of 164 companies will be added and 319 deleted from the Russell microcap index. Following notable healthcare companies will be added and deleted from Russell microcap index: Notable additio...
-- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 -- -- Received FDA Fast Track designation for KPI-012 for the treatment of PCED -- -- S...
2023-04-28 10:06:26 ET Kala Pharma's ( NASDAQ: KALA ) subsidiary Combangio has been granted $15M by the California Institute for Regenerative Medicine (CIRM) to develop KPI-012 for the treatment of persistent corneal epithelial defect. ( KALA ) has risen 9.4% . The...
MENLO PARK, Calif. and ARLINGTON, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today anno...
2023-04-12 08:53:42 ET The U.S. Food and Drug Administration (FDA) granted fast track designation to Kala Pharmaceuticals' ( NASDAQ: KALA ) human mesenchymal stem cell secretome (MSC-S) therapy KPI-012 to treat persistent corneal epithelial defect (PCED), a rare and eye disorder. ...
ARLINGTON, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that the U.S. Foo...
2023-03-29 09:31:17 ET Kala Pharma ( NASDAQ: KALA ) said it had appointed Francis Mah as the company's Chief Medical Advisor. The company said Mah would serve in the role on a part time basis and will continue his ongoing position as Director of Cornea and Exter...
ARLINGTON, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the appointment o...
News, Short Squeeze, Breakout and More Instantly...
Kala Pharmaceuticals Inc. Company Name:
KALA Stock Symbol:
NASDAQ Market:
Kala Pharmaceuticals Inc. Website:
2024-07-27 11:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is one of today's top gainers. The company's shares have moved 44.91% on the day to $6.55. Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus pe...